AACR: New CAR T cell therapy benefits patients with advanced thyroid cancers

AACR: HER2 targeted therapy shows promise in previously treated lung cancers
...
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial

AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial
AACR: Researchers share promising results from MD Anderson clinical trials
ABSTRACTS: CT012, CT132, CT265
Researchers from The University of Texas MD Anderson Cancer Center will present promising...
AACR: MD Anderson researchers share cancer breakthroughs
ABSTRACTS: 1186, 3746, 3763, 3776, 3824, 6367, 6384, 6396, 6424, 6427, 6436, 6438,
CHICAGO ― Researchers from The University of Texas...
AACR: Five MD Anderson researchers honored with 2025 Scientific Achievement Awards
Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards and honors at...
AACR: MD Anderson’s John Weinstein elected Fellow of the AACR Academy
CHICAGO ― John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology...
NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/...